News & Perspective

May 27, 2015

May 27, 2015

News Scan for May 27, 2015

Immune response to flu vaccine
Caramel apple Listeria source
Measles, rubella in Europe
Fast drug-resistance test

Dec 09, 2013

Dec 09, 2013

News Scan for Dec 09, 2013

Mideast polio vaccination
Chikungunya on St. Martin
Meningitis B vaccine
Quadrivalent flu vaccine
Leafy-greens standards
Saudi MERS patients

Mar 01, 2012

Mar 01, 2012

FDA clears first quadrivalent flu vaccine

(CIDRAP News) – The US Food and Drug Administration (FDA) yesterday approved the first quadrivalent influenza vaccine, an inhaled live attenuated influenza vaccine developed by MedImmune and modeled after its FluMist product.

The vaccine includes a second influenza B strain, which is designed to broaden protection against circulating strains. MedImmune plans to have the quadrivalent vaccine ready for the 2013-14 flu season.

Dec 13, 2011

Dec 13, 2011

Novartis says cell-based flu vaccine facility ready to produce

(CIDRAP News) – Novartis's new cell-culture based influenza vaccine factory in North Carolina has begun making a prepandemic H5N1 flu vaccine and is ready to start producing vaccines for a real pandemic when needed, the company and federal health officials announced yesterday.

The facility in Holly Springs, N.C., billed as the first of its kind in the United States, was dedicated yesterday after a long testing process.

Jul 21, 2011

Jul 21, 2011

EMA narcolepsy review restricts Pandemrix use in kids, teens

(CIDRAP) – Europe's drug regulatory agency today released its final review of a link between narcolepsy and the Pandemrix 2009 H1N1 vaccine, which recommends a labeling change that limits the vaccine's use in children and teens to when protection is needed and seasonal trivalent vaccine isn't available.

Pages

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3MAccelerate DiagnosticsGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»